[1] Jabbour TE, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists' review. World J Gastroenterol, 2019, 25(14):1653-1665. [2] Golabi P, Rhea L, Henry L, et al. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int, 2019, 13(6):688-694. [3] Budny A ,Kozłowski P , Kamińska M, et al. Epidemiology and risk factors of hepatocellular carcinoma. Pol Merkur Lekarski, 2017, 43(255):133-139. [4] Zhou F, Shang W, Yu X, et al. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev, 2018, 38(2):741-767. [5] Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604. [6] Cartier F , Indersie E , Lesjean S, et al. New tumor suppressor microRNAs target glypican-3 in human liver cancer. Oncotarget, 2017, 8(25):41211-41226. [7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):9-32. [8] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版). 中华肝脏病杂志, 2012, 20(6):929-946. [9] 曹艳, 王艳. 基于死因监测青岛市居民2008-2012年原发性肝癌死亡分析. 中华肿瘤防治杂志, 2017, 24(9):579-583. [10] 管晨滔, 赵宏, 李新庆, 等. 肝细胞癌患者的基本特征及其生存分析. 中华肿瘤杂志, 2017, 39(3):231-235. [11] 罗准, 崔巍. 肝癌分子发病机制中非编码RNA的研究进展. 中华肝脏病杂志, 2018, 26(10):797-800. [12] Wong CM, Tsang FH, Ng IO. Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat RevGastroenterol Hepatol, 2018, 15(3):137-151. [13] Delogu S, Wang C, Cigliano A, et al. SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget, 2015, 6(4):2222-2234. [14] Kress TR, Pellanda P, Pellegrinet L, et al. Identification of MYC-dependent transcriptional programs in oncogene-addicted liver tumors. Cancer Res, 2016, 76(12):3463-3472. [15] Chaisaingmongkol J, Budhu A, Dang H, et al. Common molecular subtypes among Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell, 2017, 32(1):57-70. [16] Yim SY, Shim JJ, Shin JH, et al. Integrated genomic comparison of mouse models reveals their clinical resemblance to human liver cancer. Mol Cancer Res, 2018, 16(11):1713-1723. [17] Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med, 2016, 38(1):3-15. [18] Ruf S, Heberle AM, Langelaar-Makkinje M, et al. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy, 2017, 13(3):486-505. [19] Zhao N, Maxson JE, Zhang RH, et al. Neogenin facilitates the induction of hepcidin expression by hemojuvelin in the liver. J Biol Chem, 2016, 291(23):12322-12335. [20] Liu H, Hu J, Pan H, et al. CSN5 Promotes hepatocellular carcinoma progression by SCARA5 inhibition through suppressing β-catenin ubiquitination. Dig Dis Sci, 2018, 63(1):155-165. |